Rare T263P epidermal growth factor receptor extracellular domain mutation of advanced non ‐small cell lung cancer in a Vietnamese male patient
In this study, we first report a patient with advanced lung adenocarcinoma harbouring only a rare T263P EGFR mutation who benefited from first-line afatinib therapy in Vietnam. The patient achieved a partial response with a time-to-treatment failure of 5 months. The patient subsequently received several chemotherapy regimens as the disease progressed, with overall survival of 17 months. Non-small cell lung cancer with a rare T263P EGFR mutation responds to afatinib but has a poor prognosis. AbstractT263P mutation is one of the rareEGFR mutations located on chromosome 7p11.2, which is a change in amino acid residue at position 263 of the epidermal growth factor receptor protein, where L-threonine has been replaced by L-proline. This missense mutation in the extracellular EGFR domain is not well-known in lung cancer. In this study, we first report a patient with advanced lung adenocarcinoma harbouring only a rare T263PEGFR mutation who benefited from first-line afatinib therapy in Vietnam. The patient achieved a partial response with a time-to-treatment failure of 5 months. The patient subsequently received several chemotherapy regimens as the disease progressed, with overall survival of 17 months. Non-small cell lung cancer with a rare T263PEGFR mutation responds to afatinib but has a poor prognosis. Further studies are needed to determine the efficacy of targeted therapies in this specific population.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Kien Hung Do,
Tai Van Nguyen,
Tu Anh Do,
Duc Thanh Le,
Phuong Thi Bich Nguyen,
Chu Van Nguyen Tags: CASE REPORT Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine | Study | Vietnam Health